BIOMAT Database Logo BIOMAT Database Logo

Captopril - an oral angiotensin-converting enzyme inhibitor in CHF. 1981

K Chatterjee, and J L Rouleau, and W W Parmley

UI MeSH Term Description Entries
D008134 Long-Term Care Care over an extended period, usually for a chronic condition or disability, requiring periodic, intermittent, or continuous care. Care, Long-Term,Long Term Care
D009206 Myocardium The muscle tissue of the HEART. It is composed of striated, involuntary muscle cells (MYOCYTES, CARDIAC) connected to form the contractile pump to generate blood flow. Muscle, Cardiac,Muscle, Heart,Cardiac Muscle,Myocardia,Cardiac Muscles,Heart Muscle,Heart Muscles,Muscles, Cardiac,Muscles, Heart
D010101 Oxygen Consumption The rate at which oxygen is used by a tissue; microliters of oxygen STPD used per milligram of tissue per hour; the rate at which oxygen enters the blood from alveolar gas, equal in the steady state to the consumption of oxygen by tissue metabolism throughout the body. (Stedman, 25th ed, p346) Consumption, Oxygen,Consumptions, Oxygen,Oxygen Consumptions
D011392 Proline A non-essential amino acid that is synthesized from GLUTAMIC ACID. It is an essential component of COLLAGEN and is important for proper functioning of joints and tendons. L-Proline,L Proline
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D003326 Coronary Circulation The circulation of blood through the CORONARY VESSELS of the HEART. Circulation, Coronary
D005082 Physical Exertion Expenditure of energy during PHYSICAL ACTIVITY. Intensity of exertion may be measured by rate of OXYGEN CONSUMPTION; HEAT produced, or HEART RATE. Perceived exertion, a psychological measure of exertion, is included. Physical Effort,Effort, Physical,Efforts, Physical,Exertion, Physical,Exertions, Physical,Physical Efforts,Physical Exertions
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006439 Hemodynamics The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM. Hemodynamic
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

K Chatterjee, and J L Rouleau, and W W Parmley
Efficacy of an oral angiotensin-converting enzyme inhibitor (captopril) in severe hypertension.
June 1981, Archives of internal medicine,
K Chatterjee, and J L Rouleau, and W W Parmley
[Captopril (oral inhibitor of angiotensin I converting-enzyme) in arterial hypertension].
July 1982, La Clinica terapeutica,
K Chatterjee, and J L Rouleau, and W W Parmley
First dose effect of the oral angiotensin converting enzyme inhibitor captopril.
January 1980, Archives internationales de pharmacodynamie et de therapie,
K Chatterjee, and J L Rouleau, and W W Parmley
Captopril: an oral angiotension converting enzyme inhibitor active in man.
January 1980, Archives internationales de pharmacodynamie et de therapie,
K Chatterjee, and J L Rouleau, and W W Parmley
[Angiotensin converting enzyme--captopril].
October 1979, Nihon rinsho. Japanese journal of clinical medicine,
K Chatterjee, and J L Rouleau, and W W Parmley
Captopril, an angiotensin-converting enzyme inhibitor, induced pulmonary infiltration with eosinophilia.
February 1996, Internal medicine (Tokyo, Japan),
K Chatterjee, and J L Rouleau, and W W Parmley
Control of essential hypertension with captopril, an angiotensin converting enzyme inhibitor.
May 1981, British journal of clinical pharmacology,
K Chatterjee, and J L Rouleau, and W W Parmley
Treatment of chronic congestive heart failure with captopril, an oral inhibitor of angiotensin-converting enzyme.
July 1979, The New England journal of medicine,
K Chatterjee, and J L Rouleau, and W W Parmley
Antitussive effect of captopril, an angiotensin converting enzyme inhibitor, in the rat.
September 1993, Research communications in chemical pathology and pharmacology,
K Chatterjee, and J L Rouleau, and W W Parmley
Clinical experience with the angiotensin converting enzyme inhibitor captopril.
January 1982, Clinical and experimental pharmacology & physiology. Supplement,
Copied contents to your clipboard!